RASA1: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: RASA1

NCBI ID: G5921

RASA1

RASA1: A Potential Drug Target Or Biomarker for Various Diseases

RASA1 (RASA1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, kidneys, and intestines. It is a member of the RASA1 family, which is known for its role in cell signaling and regulation. RASA1 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The RASA1 protein is composed of 215 amino acid residues and has a molecular weight of 24.1 kDa. It is located in the cytoplasm and is involved in various cellular processes, including cell signaling, cell adhesion, and intracellular signaling. RASA1 is a G protein-coupled receptor (GPCR), which means that it interacts with intracellular signaling molecules, such as GTP, and activates downstream signaling pathways.

RASA1 has been shown to play a role in various physiological processes in the body, including the regulation of pain, inflammation, and cell survival. It is involved in the development and maintenance of the blood-brain barrier, which is responsible for separating the brain from the body and providing a barrier to harmful substances. RASA1 is also involved in the regulation of cell growth and differentiation, as well as in the regulation of neurotransmitter release and signaling.

In addition to its role in cell signaling and regulation, RASA1 has also been identified as a potential drug target or biomarker for various diseases. For example, RASA1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is also involved in the development and progression of cancer, including neuroendocrine tumors.

In addition to its potential as a drug target or biomarker, RASA1 has also been identified as a potential therapeutic agent for the treatment of various diseases. For example, RASA1 has been shown to reduce the symptoms of Alzheimer's disease in animal models, and it is currently being tested as a potential therapeutic agent for this disease in human clinical trials. Similarly, RASA1 has been shown to reduce the symptoms of Parkinson's disease in animal models, and it is currently being tested as a potential therapeutic agent for this disease in human clinical trials.

Overall, RASA1 (RASA1_HUMAN) is a protein that is involved in various cellular processes in the body, including cell signaling and regulation. It has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of RASA1 in these diseases and to develop effective therapeutic agents for the treatment of these conditions.

Protein Name: RAS P21 Protein Activator 1

Functions: Inhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1

The "RASA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets